Finance

Coupang trades at a fraction of MercadoLibre’s sales multiple, but the Latin American fintech giant generates far superior margins and cash flow.

Abbott has a low-risk profile with significant upside potential.

Tilray’s stock isn’t the bargain it appears to be at first.

The two earlier streaks like it both ended with a down year of over 30%. Is today’s run built any differently?

CrowdStrike trades at a steep premium despite ongoing profitability challenges, while UiPath has just turned profitable with a valuation multiple a fraction of its rival’s.

Investors should be thinking about monetization strategies.

Shares have moved lower by 3% so far this month.

IHE concentrates 23.6% in Eli Lilly and delivers 1.4% yield, while XPH spreads risk across 62 holdings with a lower 0.35% expense ratio.

SpaceX must prove its AI spending is worth the near-term pain.

A couple of popular institutional trades are driving much of the purchasing activity.

NEAR Protocol is soaring in value this year, but how long can it keep up this performance?

BBH concentrates on 25 large-cap biotech leaders, while XPH diversifies across 62 pharmaceutical holdings. Both charge 0.35% annually, but their five-year returns diverged significantly.

Viking’s weight loss pill program has a couple of issues, including the fierce competitors who have a big head start.

The LEO satellite developer still has plenty of upside potential.

Pay close attention so you don’t miss out on any key details.

It plays a critical role in AI development.

Zcash’s trajectory suggests that even bigger gains are on the way.

An Anthropic IPO will boost several companies.

What does it mean for shareholders when a chipmaker can’t make processors fast enough?

Hybrid-electric demonstrator nears completion as cash runway extends to 24 months.